GlaxoSmithKline/Adolor Entereg Resubmission Pushed Out To Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Response to November “approvable” letter for postoperative ileus NDA will take an additional quarter following an FDA request for more data in the resubmission.
You may also be interested in...
FDA Lets GSK/Adolor Resume Entereg Work
But regulatory hurdles could send GSK on its way, analysts say.
FDA Lets GSK/Adolor Resume Entereg Work
But regulatory hurdles could send GSK on its way, analysts say.
FDA Accepts Adolor/GSK Entereg Resubmission For Postoperative Ileus
Sponsors’ response to FDA clinical holds on the alvimopan program contain “substantially the same” information as the resubmitted NDA, Adolor tells “The Pink Sheet” DAILY.